Heart Valves Companies

Edwards Lifesciences Received FDA approval for the first-ever transcatheter mitral valve replacement (TMVR) system with a self-expanding anchor, potentially expanding treatment options for patients with mitral valve regurgitation. Announced positive initial results from its PARTNER 3 IDE clinical trial, demonstrating the safety and efficacy of its third-generation transcatheter aortic valve (TAVR) system.

Abbott Launched its newest transcatheter aortic valve (TAVR) system, offering improved delivery and positioning features for surgeons. Entered into a strategic partnership with Medtronic to develop and commercialize new heart valve technologies.

Medtronic Received FDA approval for its Hugo™ robotic surgery platform, designed for use in minimally invasive procedures like heart valve surgeries, potentially expanding market reach. Announced the expansion of its CoreValve Evolut transcatheter aortic valve (TAVR) system family with the introduction of a new low-profile valve option.

Boston Scientific Received CE Mark approval for its Lotus Edge™, a next-generation transcatheter aortic valve (TAVR) system with a unique anchor design, targeting specific patient anatomies. Expanded its presence in the tricuspid valve replacement market with the acquisition of Claret Medical, further diversifying its portfolio.

• Edwards Lifesciences Corporation


• Abbott


• Medtronic


• LivaNova PLC


• Boston Scientific Corporation


• CryoLife, Inc.


• Micro Interventional Devices, Inc.